CA19-9 versus CA-125 in Endometriosis

Tharwa H. Hassan AL-Tai, Hayfaa S. AL-Hadithi, Hind S. Abdulsalam
In: IOSR Journal of Dental and Medical Sciences · 2014 · vol. 13(4) , pp. 27–30 · doi:10.9790/0853-13432730 · W2313240635
article OA: bronze CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study compared serum CA19-9 and CA-125 levels in 51 women with endometriosis against 33 healthy controls to evaluate their diagnostic effectiveness.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: -Endometriosis is a condition characterized by the presence of endometrial tissue in ectopic foci outside the uterus. The lesions are not cancerous, but they can develop to the point that they cause obstruction or adhesion that attach to nearby organs, causing pain, inflammation, and sometimes infertility. Recently a tumor marker has been used in endometriosis which is CA-125 (cancer antigen or carbohydrate antigen 125). Objective:-To evaluate the affectivity of serum CA19-9versus serum CA-125in the diagnosis of endometriosis. Patients and methods: -This study applied on 51women with endometriosis compared to 33 healthy women as control group starting from November 2011 to end of January 2012.Their serum samples were collected to investigate serum concentrations of CA-125 and CA19-9 by using ELISA technique.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK